Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease

NCT01249820 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Myelodysplastic Syndrome
Leukemia, Myeloid, Acute

Interventions

DRUG: anidulafungin 200 mg q48h
DRUG: anidulafungin 300 mg q72h

Sponsor

Radboud University Medical Center